Allt inom mfn-ext-nq-company-announcement

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

  • Nanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.
  • Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.

Read more

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.